
    
      All subjects will receive a SC dose of either investigational product or placebo as the first
      dose on day 1.

      Subjects who are determined to be non-responders in Part A will receive tezepelumab SC Q2W
      following completion of all week 16 study activities. Nonresponders are defined as those
      subjects who have not achieved at least a 50% improvement in EASI at week 16 compared to
      baseline (day 1).

      Safety follow-up is 18 weeks after the EOT visit (20 weeks after the final dose of
      investigational product).
    
  